Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850139 | 0.86 | — | — | |
| SCHEMBL11850381 | 0.82 | L3MBTL1 (0.30) | — | |
| SCHEMBL11884347 | 0.82 | — | — | |
| SCHEMBL22991785 | 0.82 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL4389933 | 0.79 | — | — | |
| SCHEMBL26084002 | 0.78 | — | — | |
| SCHEMBL10639828 | 0.78 | — | — | |
| SCHEMBL4063062 | 0.78 | EPHX1 (0.32) | — | |
| SCHEMBL3391990 | 0.78 | — | — | |
| SCHEMBL4620512 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081207-B1 | USE OF A LIPOSOME COMPOSITION | SYMRISE AG (DE) | 2022-09-21 | — | — | EP | claimed |
| EP-2932858-A1 | Homovanillic acid esters, in particular for achieving an impression of heat and/or spiciness | Symrise AG (DE) | 2015-10-21 | — | — | EP | claimed |
| US-8569383-B2 | Utilization of rhinologically active substances | SYMRISE AG (DE) | 2013-10-29 | — | — | US | claimed |
| EP-1341512-B1 | RHINOLOGICAL AGENTS | SYMRISE GMBH & CO KG (DE) | 2008-12-31 | — | — | EP | claimed |
| US-20080274064-A1 | UTILIZATION OF RHINOLOGICALLY ACTIVE SUBSTANCES | SYMRISE GMBH & CO. KG (DE) | 2008-11-06 | — | — | US | claimed |
| US-7414079-B2 | Utilization of rhinologically active substances | SYMRISE GMBH & CO. KG (DE) | 2008-08-19 | — | — | US | claimed |
| US-20050027017-A1 | Rhinologically active substances | SYMRISE AG (DE) | 2005-02-03 | — | — | US | claimed |
| EP-1341512-A1 | RHINOLOGICAL AGENTS | HAARMANN & REIMER GMBH (DE) | 2003-09-10 | — | — | EP | claimed |
| WO-2002041861-A1 | RHINOLOGICAL AGENTS | HAARMANN & REIMER GMBH (DE) | 2002-05-30 | — | — | WO | claimed |
| EP-4103144-B1 | COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4192614-B1 | PROCESS FOR THE PREPARATION OF MICROCAPSULES | SYMRISE AG (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4110277-B1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3045161-B1 | Use of active mixtures of 1,2-hexanediol and 1,2-octanediol in cosmetic, pharmaceutical or dermatological emulsions | SYMRISE AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4025675-B1 | A PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-20080096969-A1 | N alpha-(Menthanecarbonyl)amino acid amides and use thereof as physiological cooling active ingredients | SYMRISE GMBH & CO. KG (DE) | 2008-04-24 | — | — | US | disclosed |
| US-20080095719-A1 | Blackberry Extract | SYMRISE GMBH & CO. KG (DE) | 2008-04-24 | — | — | US | disclosed |
| EP-1913976-A1 | N-alpha-(menthane carbonyl) amino acid amides and their use as physiological coolants | Symrise GmbH & Co. KG (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20080085246-A1 | Use of Eugenol Acetate as an Agent Against Bad Breath | SYMRISE GMBH & CO. KG (DE) | 2008-04-10 | — | — | US | disclosed |
| US-20070218016-A1 | Use of Aroma Substance Mixtures as Agents Against Bad Breath | SYMRISE GMBH & CO. KG (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20050027017-A1 | Rhinologically active substances | SYMRISE AG (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274064-A1 | UTILIZATION OF RHINOLOGICALLY ACTIVE SUBSTANCES | MRGPRX4, HCRTR1, TRPV1 | SLC6A4 1530/4885SLC6A3 1526/4885 |
| US-20070218016-A1 | Use of Aroma Substance Mixtures as Agents Against Bad Breath | BAD, BAX, BAK1 | SLC6A4 3001/4885SLC6A3 3122/4885 |
| US-20050027017-A1 | Rhinologically active substances | TRPV1, TRPA1, CRH | SLC6A4 1453/4885SLC6A3 1568/4885 |
| US-20080096969-A1 | N alpha-(Menthanecarbonyl)amino acid amides and use thereof as physiological cooling active ingredients | NMBR, RIMKLA, NAAA | SLC6A4 2217/4885SLC6A3 3857/4885 |
| US-20080085246-A1 | Use of Eugenol Acetate as an Agent Against Bad Breath | BAD, BAX, CAT | SLC6A4 4655/4885SLC6A3 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.